Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

Cisplatin 98pembrolizumab 79Radiotherapy 49Carboplatin 41Magnetic Resonance Spectroscopy 37toripalimab 34Radiotherapy, Intensity-Modulated 34Gemcitabine 29Docetaxel 28Cetuximab 28Specimen Handling 26Surgical Procedures, Operative 23Paclitaxel 23Fluorouracil 22Radiation 20Nivolumab 20Biopsy 18Drug Therapy 17Chemoradiotherapy 17Blood Specimen Collection 17Capecitabine 15Standard of Care 14tislelizumab 13Surveys and Questionnaires 13Platinum 13camrelizumab 12nimotuzumab 11Immune Checkpoint Inhibitors 11130-nm albumin-bound paclitaxel 111,2-diaminocyclohexaneplatinum II citrate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Taxoids × Head & Neck × Clear all
NCT05726370 2025-06-22

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
28 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡